EUVIMEDEUVIMED entdecken
Crossref

EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges

Mingjia Li, Dwight H. Owen, Gregory A. Otterson

AME Clinical Trials Review · 2023

DOI: 10.21037/actr-23-30 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Mingjia Li und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Li, M., Owen, D. H., & Otterson, G. A. (2023). EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-30

Vancouver

Li M, Owen DH, Otterson GA. EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-30

BibTeX
@article{Li2023,
  author = {Li, Mingjia and Owen, Dwight H. and Otterson, Gregory A.},
  title = {EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges},
  journal = {AME Clinical Trials Review},
  year = {2023},
  doi = {10.21037/actr-23-30}
}
Kostenlos starten →